Get the Daily Brief
Latest Biotech News
Roche flags China pricing pain; diagnostics sales pressured this year
Roche reported diagnostics revenues down 4% year‑to‑date and told investors that China's volume‑based procurement and diagnostic‑related group audits materially hit pricing and volumes in 2025....
Electra bags $183M Series C to advance rare‑disease and HLH programs
Electra Therapeutics closed a $183 million Series C to fund pivotal testing of its lead monoclonal antibody ELA026 for secondary hemophagocytic lymphohistiocytosis (HLH) and to advance additional...
Merck KGaA to exit Arklow API work — plant slated to close 2028
Merck KGaA announced it will wind down active pharmaceutical ingredient (API) production at its Arklow, Ireland site and proposed closing the factory at the end of 2028, the company told Endpoints...
Alector slashes workforce: GSK-linked antibody fails Phase III
Alector said a GSK-partnered antibody failed a pivotal Phase III study and the company will cut roughly half its staff as it ends development of that asset. The Bay Area biotech also announced...
Moderna’s CMV shot... Phase 3 failure forces program halt
Moderna reported that its cytomegalovirus (CMV) vaccine failed to meet its primary efficacy endpoint in a large Phase III trial and said it will stop most development of the program. The...
Ventyx’s NLRP3 inhibitor cuts inflammation 78% — stock jumps
Ventyx Biosciences reported Phase 2 data showing its oral NLRP3 inhibitor VTX3232 produced a dramatic 78% reduction in high-sensitivity C‑reactive protein (hsCRP) over 12 weeks as a monotherapy,...
Flagship launches Expedition Medicines: $50M to back covalent drug discovery
Flagship Pioneering launched Expedition Medicines with a $50 million commitment to build an AI-driven platform focused on covalent small-molecule drug discovery, the firm said. Expedition emerges...
Retrons repurposed: bacterial elements enable broad DNA editing
Researchers unveiled new gene‑editing approaches that repurpose bacterial retrons—reverse transcriptase-based elements that produce multicopy single‑stranded DNA—for precise and scalable genome...
Engineered CASTs boost precision gene insertion — activity up to fourfold
A team engineering CRISPR-associated transposons (CASTs) reported a high-throughput dual genetic screen that quantified activity and specificity across large CAST variant libraries. The screen...
Live embryo imaging reveals mitotic errors in placenta-fated cells
New optimized live‑imaging methods for human preimplantation embryos revealed chromosome segregation errors arising de novo in cells that later populate the placenta, according to two...
Tango moves pancreatic cancer asset into Phase 3 — raises $225M
Tango Therapeutics reported data that it judged sufficient to advance its pancreatic cancer candidate into a Phase 3 program and concurrently raised $225 million to fund development. The company...
Takeda inks $11.4B Innovent deal: $1.2B up front for oncology candidates
Takeda agreed to a major licensing and co‑development pact with Innovent Biologics, committing $1.2 billion up front and up to $11.4 billion in total consideration to access up to three...
Moderna CMV flop: company halts most development after phase 3 miss
Moderna announced that its cytomegalovirus (CMV) mRNA vaccine failed to meet primary efficacy endpoints in a Phase 3 trial and the company will stop most development of the program. The company...
Arcturus inhaled mRNA disappoints: cystic fibrosis interim data miss
Arcturus Therapeutics released interim results from a Phase 2 study of ARCT‑032, its inhaled mRNA therapy for cystic fibrosis, and the data did not show meaningful improvement in lung function...
Alector hits wall: Phase III fail triggers layoffs and leadership exits
Alector reported that its GSK‑partnered antibody failed to slow progression in a Phase 3 dementia study, triggering a major corporate retrenchment. The Bay Area biotech said it will discontinue...
Takeda‑Innovent pact: $1.2B upfront, $11.4B deal reshapes oncology bets
Takeda agreed to a major oncology collaboration and licensing arrangement with Innovent Biologics, paying $1.2 billion up front and structuring potential payments that could total roughly $11.4...
Roche trims early oncology, flags diagnostics headwinds in Q3
Roche disclosed a pipeline cleanup — removing five Chugai‑origin assets including four early solid‑tumor programs and an anti‑IL‑8 candidate for endometriosis — while reporting a 4% year‑to‑date...
NLRP3 inhibitor posts rapid biomarker wins — Ventyx stock soars
Ventyx Biosciences reported Phase 2 biomarker results showing its oral NLRP3 inhibitor VTX3232 produced an almost 80% reduction in hsCRP within one week and a 78% monotherapy reduction over 12...
Long‑read metagenomics tracks donor strains after FMT — new LongTrack pipeline
Researchers at the Icahn School of Medicine at Mount Sinai unveiled LongTrack, a long‑read metagenomic sequencing pipeline (Oxford Nanopore and PacBio) that resolves strain‑level engraftment and...
Retrons for precision editing: metagenomic screen yields therapeutic editors
A pair of studies revealed retrons as a new, engineerable class of reverse‑transcribing elements for precise genome editing. A metagenomic screen identified retron reverse transcriptases with...